Octyl itaconate inhibits osteoclastogenesis by suppressing Hrd1 and activating Nrf2 signaling.
Sun X, Zhang B, Pan X, Huang H, Xie Z, Ma Y, Hu B, Wang J, Chen Z, Shi P.
Sun X, et al. Among authors: chen z.
FASEB J. 2019 Nov;33(11):12929-12940. doi: 10.1096/fj.201900887RR. Epub 2019 Sep 6.
FASEB J. 2019.
PMID: 31490085
Free PMC article.
In summary, OI, an itaconate derivative, can inhibit osteoclastogenesis in vitro and in vivo, indicating that OI could be a potential drug to treat osteoclast-related diseases; our results also link itaconate to the development of osteoporosis.-Sun, X., Zhang, B., Pan, X., Huang, …
In summary, OI, an itaconate derivative, can inhibit osteoclastogenesis in vitro and in vivo, indicating that OI could be a potential drug t …